Genmab — April 2017
-
så længe SGEN ikke har bestemt sig omkring opt-in, så er der nok ikke noget specielt saftigt på tisotumab
-
der er ingen fordel for GEN i at tale værdien op, inden SGEN skal beslutte sig
-
-
"Positive Opinion adopted by consensus on 06.04.2017"
-
no clue what this means in terms of the EMEA / CHMP process?
-
er det ikke agenda for chmp kommitteen? det er kommissionen, der skal give godkendelsen. chmp har allerede gjort deres
-
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001595.jsp&mid=WC0b01ac0580b18a3d#Steps involved in obtaining an EU marketing authorisation
-
det øverste link fungerede ikke - check i bunden af siden
-
mandag 1. maj bør være den absolutte bagkant for approval beslutningen
-
mon ikke de får lidt kolde fødder ved tanken om den acceleration dara viser i markedet - og det relativt tynde ansøgningsmateriale, der bliver sendt frem til dem?
-
så kommer kl 1400 hugget igen på klokkeslet
Lidt konservativt måske. ? 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind